Rameda Pharmaceuticals
Sherif Atteya is an accomplished professional in the pharmaceutical industry, currently serving as Business Unit Manager at BIOMED Pharmaceuticals since December 2022 and Head of the Marketing Department at Splendid Pharma since September 2021. At Bioxell-Pharmaceutical and Mash Premiere, Sherif has held the role of Marketing Head since September 2019 and February 2018, respectively. Additionally, Sherif has been the Group Product Manager at International Drug Agency for Pharmaceutical Industry since August 2017 and has held multiple positions at Rameda Pharmaceuticals since January 2008, including Marketing Lead and Key Account Lead. The experience in the industry began as a medical representative, achieving significant results with various products. Sherif holds an MBA in Marketing from John Sulston Business School and has a strong academic background, including degrees from prestigious institutions such as the University of Pennsylvania and Maastricht University.
This person is not in any offices
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.